Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.82 |
| ▸ | BTK | Q06187 | 9/20 | 0.82 |
| ▸ | ITK | Q08881 | 7/20 | 0.76 |
| ▸ | JAK2 | O60674 | 1/20 | 0.66 |
| ▸ | LYN | P07948 | 1/20 | 0.66 |
| ▸ | TEC | P42680 | 1/20 | 0.66 |
| ▸ | TXK | P42681 | 1/20 | 0.66 |
| ▸ | BMX | P51813 | 1/20 | 0.66 |
| ▸ | JAK3 | P52333 | 1/20 | 0.66 |
| ▸ | CD69 | Q07108 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14769280 | 0.93 | EGFR (0.81) | EGFRBTKITK | |
| SCHEMBL2346314 | 0.90 | EGFR (1.00) | EGFRBTKITKJAK2LYN | |
| SCHEMBL28080977 | 0.90 | BTK (0.88) | EGFRBTKITKJAK3 | |
| SCHEMBL26158821 | 0.90 | EGFR (0.82) | EGFRBTKITKJAK2LYN | |
| SCHEMBL2352426 | 0.90 | BTK (1.00) | EGFRBTKITKJAK3 | |
| SCHEMBL2230183 | 0.90 | BTK (1.00) | EGFRBTKITKJAK3 | |
| SCHEMBL13165498 | 0.89 | BTK (0.70) | EGFRBTKITKJAK3 | |
| SCHEMBL14769288 | 0.88 | EGFR (0.82) | EGFRBTKITK | |
| SCHEMBL13165494 | 0.88 | BTK (0.84) | EGFRBTKITKJAK3 | |
| SCHEMBL9923758 | 0.88 | EGFR (0.82) | EGFRBTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987276-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-06-05 | — | — | US | disclosed |
| US-9987276-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-06-05 | — | — | US | disclosed |
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-20 | — | — | US | disclosed |
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885BTK 594/4885ITK 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.